A delayed clinical trial actually boosted Bristol Myers Squibb’s stock.
Here’s why.
-
Bristol Myers’ stock rallied Wednesday as investors maintained high hopes
for Cobenfy as an Alzheimer’s treatment, even though the outcome of a
late-stage ...
34 minutes ago









....TECHNICALLY, ....SYNCHRONIZED.
ReplyDelete